Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John C Byrd

Showing results (31-40 of 681) with videos related to

Pageof 69
Sort By:
Advances in Pharmacology (San Diego, Calif.)|October 7, 2004
Monoclonal antibody therapy in lymphoid leukemiasThomas S Lin, John C Byrd
Blood|July 28, 2021
Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignanciesDeborah M Stephens, John C Byrd
Leukemia & Lymphoma|March 16, 2013
Emerging drug profile: cyclin-dependent kinase inhibitorsJames S Blachly, John C Byrd
Oncology (Williston Park, N.Y.)|January 22, 2013
Chronic lymphocytic leukemia with del(17p13.1): a distinct clinical subtype requiring novel treatment approachesDeborah M Stephens, John C Byrd
Hematology/Oncology Clinics of North America|April 9, 2013
Improving the treatment outcome of patients with chronic lymphocytic leukemia through targeted antibody therapyDeborah M Stephens, John C Byrd
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2007
Have we forgotten the purpose of phase III studies?Joseph M Flynn, John C Byrd
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2014
New strategies in chronic lymphocytic leukemia: shifting treatment paradigmsFarrukh T Awan, John C Byrd
Nature Reviews. Clinical Oncology|May 20, 2021
Whole-genome sequencing for myeloid disease: one assay to stratify them all?Karilyn T M Larkin, John C Byrd
Seminars in Hematology|July 15, 2005
Decitabine in chronic leukemiasJean-Pierre J Issa, John C Byrd
Future Oncology (London, England)|June 9, 2025
How well does acalabrutinib work and how safe is it to treat patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have had previous treatments? a plain language summary of 2 key studiesJohn C Byrd, Shweta Hakre, Paolo Ghia
Pageof 69

Showing results (31-40 of 681) with videos related to

Sort By:
Pageof 69
Advances in Pharmacology (San Diego, Calif.)|October 7, 2004
Monoclonal antibody therapy in lymphoid leukemiasThomas S Lin, John C Byrd
Blood|July 28, 2021
Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignanciesDeborah M Stephens, John C Byrd
Leukemia & Lymphoma|March 16, 2013
Emerging drug profile: cyclin-dependent kinase inhibitorsJames S Blachly, John C Byrd
Oncology (Williston Park, N.Y.)|January 22, 2013
Chronic lymphocytic leukemia with del(17p13.1): a distinct clinical subtype requiring novel treatment approachesDeborah M Stephens, John C Byrd
Hematology/Oncology Clinics of North America|April 9, 2013
Improving the treatment outcome of patients with chronic lymphocytic leukemia through targeted antibody therapyDeborah M Stephens, John C Byrd
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2007
Have we forgotten the purpose of phase III studies?Joseph M Flynn, John C Byrd
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2014
New strategies in chronic lymphocytic leukemia: shifting treatment paradigmsFarrukh T Awan, John C Byrd
Nature Reviews. Clinical Oncology|May 20, 2021
Whole-genome sequencing for myeloid disease: one assay to stratify them all?Karilyn T M Larkin, John C Byrd
Seminars in Hematology|July 15, 2005
Decitabine in chronic leukemiasJean-Pierre J Issa, John C Byrd
Future Oncology (London, England)|June 9, 2025
How well does acalabrutinib work and how safe is it to treat patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have had previous treatments? a plain language summary of 2 key studiesJohn C Byrd, Shweta Hakre, Paolo Ghia
Pageof 69